Milestone

About

Nanjing Milestone Pharma Co., based in China, specializes in pharmaceutical testing and quality research, providing essential analytical and optimization services to support drug development processes.Founded in 2016, Nanjing Milestone Pharma Co. operates as an integrated platform for drug quality research technology. The company is headquartered in Nanjing, China. In December 2025, Milestone was fully acquired by GL Ventures, aiming to enhance its infrastructure and increase research capacity. The company has completed one deal to date.Milestone operates as an integrated drug quality research technology platform, specializing in the development and optimization of pharmaceutical products and services. They provide analytical and testing solutions that meet the complex regulatory requirements of the pharmaceutical industry. Their services include advanced quality control assessments, stability testing, and formulation development tailored for drug manufacturers and developers. The main users of these services encompass pharmaceutical companies, contract research organizations (CROs), and biotechnology firms globally, with strong markets in North America, Europe, and parts of Asia.Milestone's revenue structure primarily stems from B2B transactions, collaborating directly with pharmaceutical and biotech firms on quality research and development projects. Clients enter into contractual agreements that define the scope of services and costs, fostering customized solutions that often lead to long-term partnerships. Their flagship offerings include comprehensive testing and analytical services critical for regulatory submissions, with pricing structured around the complexity of services provided, reflecting the bespoke nature of their work.In December 2025, following its acquisition by GL Ventures, Milestone aims to leverage this partnership to expand its capabilities in pharmaceutical testing and quality research services. This strategic move is intended to bolster existing infrastructure supporting drug development and enhance its position within the CXO service chain. The acquisition will enable Milestone to increase its capacity and advance its quality research capabilities, positioning the company for growth in new markets and enhancing its service offerings.